Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of early response and safety of crisugabalin besilate in neuropathic pain
ChiCTR2500100765Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of crisugabalin besilate in Neuralgia, sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Change from baseline in daily NRS scores over 1 week and Change from baseline in pain NRS score at 4 weeks. Started Apr 2025; status: recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
Neuralgia
Beyond the preview
Go deeper on ChiCTR2500100765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100765.